Literature DB >> 30967621

B cell checkpoints in autoimmune rheumatic diseases.

Samuel J S Rubin1,2,3, Michelle S Bloom1,2,3, William H Robinson4,5,6.   

Abstract

B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen-presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co-engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30967621     DOI: 10.1038/s41584-019-0211-0

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  131 in total

Review 1.  B-cell targeted therapies in human autoimmune diseases: an updated perspective.

Authors:  Michael J Townsend; John G Monroe; Andrew C Chan
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 3.  How B cells capture, process and present antigens: a crucial role for cell polarity.

Authors:  Maria-Isabel Yuseff; Paolo Pierobon; Anne Reversat; Ana-Maria Lennon-Duménil
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

Review 4.  The central and multiple roles of B cells in lupus pathogenesis.

Authors:  O T Chan; M P Madaio; M J Shlomchik
Journal:  Immunol Rev       Date:  1999-06       Impact factor: 12.988

5.  Properties of rhodopsin dependent on associated phospholipid.

Authors:  M Zorn; S Futterman
Journal:  J Biol Chem       Date:  1971-02-25       Impact factor: 5.157

6.  Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Authors:  Ulrich Specks; Peter A Merkel; Philip Seo; Robert Spiera; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Barri J Fessler; Linna Ding; Lisa Viviano; Nadia K Tchao; Deborah J Phippard; Adam L Asare; Noha Lim; David Ikle; Brett Jepson; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Mark Mueller; Lourdes P Sejismundo; Kathleen Mieras; John H Stone
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

7.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Authors:  Brad H Rovin; Richard Furie; Kevin Latinis; R John Looney; Fernando C Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P Garg; Paul Brunetta; Gerald Appel
Journal:  Arthritis Rheum       Date:  2012-01-09

8.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

9.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

10.  Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Authors:  Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael R Ehrenstein; Martin Salden; Mark Bodman-Smith; Anthony D B Webster
Journal:  Arthritis Rheum       Date:  2003-08
View more
  19 in total

1.  CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.

Authors:  Yuki Imura; Makoto Ando; Taisuke Kondo; Minako Ito; Akihiko Yoshimura
Journal:  JCI Insight       Date:  2020-07-23

Review 2.  Epigenetic regulation of B cells and its role in autoimmune pathogenesis.

Authors:  Fan Xiao; Ke Rui; Xiaofei Shi; Haijing Wu; Xiaoyan Cai; Kathy O Lui; Qianjin Lu; Esteban Ballestar; Jie Tian; Hejian Zou; Liwei Lu
Journal:  Cell Mol Immunol       Date:  2022-10-12       Impact factor: 22.096

3.  T1D patient-derived hematopoietic stem cells are programmed to generate Tph, Tfh, and autoimmunity-associated B cell subsets in human immune system mice.

Authors:  Andrea Vecchione; Rachel Madley; Nichole Danzl; Chiara Borsotti; Mohsen Khosravi Marharlooei; Hao-Wei Li; Grace Nauman; Xiaolan Ding; Siu-Hong Ho; Georgia Fousteri; Megan Sykes
Journal:  Clin Immunol       Date:  2022-05-26       Impact factor: 10.190

4.  Gm40600 promotes CD4+ T-cell responses by interacting with Ahnak.

Authors:  Youdi He; Ying Fang; Bing Zhai; Xiaoling Liu; Gaizhi Zhu; Shan Zhou; Yaqi Xu; Xiaoqian Wang; Wenting Su; Renxi Wang
Journal:  Immunology       Date:  2021-06-02       Impact factor: 7.215

Review 5.  Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders.

Authors:  Alicia Zou; Sudarshini Ramanathan; Russell C Dale; Fabienne Brilot
Journal:  Cell Mol Immunol       Date:  2020-07-29       Impact factor: 22.096

Review 6.  RhoA as a Key Regulator of Innate and Adaptive Immunity.

Authors:  Matthias Bros; Katharina Haas; Lorna Moll; Stephan Grabbe
Journal:  Cells       Date:  2019-07-17       Impact factor: 6.600

Review 7.  Frontiers of Autoantibodies in Autoimmune Disorders: Crosstalk Between Tfh/Tfr and Regulatory B Cells.

Authors:  Tingting Ding; Rui Su; Ruihe Wu; Hongwei Xue; Yanyan Wang; Ronghui Su; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  Front Immunol       Date:  2021-03-26       Impact factor: 7.561

Review 8.  B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells.

Authors:  Carlo G Bonasia; Wayel H Abdulahad; Abraham Rutgers; Peter Heeringa; Nicolaas A Bos
Journal:  Cells       Date:  2021-05-13       Impact factor: 6.600

9.  Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis.

Authors:  Borja Hernández-Breijo; Chamaida Plasencia-Rodríguez; Victoria Navarro-Compán; Carlota García-Hoz; Israel Nieto-Gañán; Cristina Sobrino; Javier Bachiller-Corral; Mariana Díaz-Almirón; Ana Martínez-Feito; Teresa Jurado; Paloma Lapuente-Suanzes; Gema Bonilla; Cristina Pijoán-Moratalla; Garbiñe Roy; Mónica Vázquez-Díaz; Alejandro Balsa; Luisa M Villar; Dora Pascual-Salcedo; Eulalia Rodríguez-Martín
Journal:  Front Med (Lausanne)       Date:  2021-06-17

10.  "Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation".

Authors:  Geoff D E Cuvelier; Amanda Li; Sibyl Drissler; Amina Kariminia; Sayeh Abdossamadi; Jacob Rozmus; Jean-Pierre Chanoine; Bernard Ng; Sara Mostafavi; Ryan R Brinkman; Kirk R Schultz
Journal:  Front Immunol       Date:  2020-10-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.